U.S., Dec. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07293754) titled 'An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors' on Dec. 03.
Brief Summary: This is an early phase trial designed to evaluate the safety, tolerability, and preliminary antitumor activity of RPTR-1-201 in adults with advanced solid tumors. The trial includes dose escalation and dose expansion parts and will evaluate RPTR-1-201 as monotherapy and in combination with an anti-PD-1 monoclonal antibody.
Study Start Date: Dec. 15
Study Type: INTERVENTIONAL
Condition:
Advanced Malignant Solid Tumor
Intervention:
DRUG: RPTR-1-201
RPTR-1-201
DRUG: PD-1 / PD-L1 monoclonal antibody
PD-1/PD-L1 monoclonal antibody
Recruitmen...